These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30987257)

  • 41. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
    Lee YS; Johnson DE; Grandis JR
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.
    Schmitz S; Ang KK; Vermorken J; Haddad R; Suarez C; Wolf GT; Hamoir M; Machiels JP
    Cancer Treat Rev; 2014 Apr; 40(3):390-404. PubMed ID: 24176789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
    Okuyama K; Naruse T; Yanamoto S
    J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.
    Tathineni P; Joshi N; Jelinek MJ
    Curr Treat Options Oncol; 2023 Jun; 24(6):680-692. PubMed ID: 37067660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immuno-oncology of head and neck tumors].
    Kasper S; Hussain T; Virchow I; Stuschke M; Lang S
    HNO; 2019 Mar; 67(3):221-235. PubMed ID: 30635676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma.
    Manukian G; Bar-Ad V; Lu B; Argiris A; Johnson JM
    Front Oncol; 2019; 9():122. PubMed ID: 30895168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Humphries A; Zhou CJ; Welsh M; Lem M; Kang H; Algazi AP
    Head Neck; 2024 Feb; 46(2):321-327. PubMed ID: 37997549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
    Kao HF; Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
    Blick SK; Scott LJ
    Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
    Kitamura N; Sento S; Yoshizawa Y; Sasabe E; Kudo Y; Yamamoto T
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.
    Okano S
    Auris Nasus Larynx; 2024 Aug; 51(4):684-695. PubMed ID: 38729034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.